Cart
sales@molnova.com
BMS-833923
CAS No. 1059734-66-5
BMS-833923( XL-139 )
Catalog No. M17789 CAS No. 1059734-66-5
BMS-833923, an orally bioavailable Smoothened antagonist, inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner (IC50: 21 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 41 | In Stock |
|
| 10MG | 67 | In Stock |
|
| 25MG | 116 | In Stock |
|
| 50MG | 187 | In Stock |
|
| 100MG | 338 | In Stock |
|
| 200MG | 498 | In Stock |
|
| 500MG | 790 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBMS-833923
-
NoteResearch use only, not for human use.
-
Brief DescriptionBMS-833923, an orally bioavailable Smoothened antagonist, inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner (IC50: 21 nM).
-
DescriptionBMS-833923, an orally bioavailable Smoothened antagonist, inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner (IC50: 21 nM).
-
In Vitro——
-
In Vivo——
-
SynonymsXL-139
-
PathwayApoptosis
-
TargetIL Receptor
-
RecptorSmoothened
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1059734-66-5
-
Formula Weight473.57
-
Molecular FormulaC30H27N5O
-
Purity>98% (HPLC)
-
SolubilityDMSO : 50 mg/mL 105.58 mM;
-
SMILESc12c(c(nc(n1)Nc1ccc(cc1)C(=O)Nc1cc(ccc1C)CNC)c1ccccc1)cccc2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Tang JY, et al. Semin Cutan Med Surg. 2011, 30(4 Suppl), S14-18.2. Zaidi AH, et al. Y Invest. 2013, 31(7), 480-489.
molnova catalog
related products
-
Apilimod
Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis.
-
IL-4-inhibitor-1
IL-4 inhibitor is an inhibitor of IL-4.1It binds to IL-4 with a Kdvalue of 1.8 μM and inhibits IL-4 activity in a cell-based reporter assay (EC50= 1.81 μM).
-
GSK717
GSK717 is a potent and selective inhibitor of nucleotide-binding oligomerization domain 2 (NOD2). GSK717 blocks synergy between NOD2 and TLR2. GSK717 does not affect NOD1, TNFR1 and TLR2-mediated responses.
